Trade Hikma Pharmaceuticals PLC - HIK CFD

Discover the latest Hikma share price today with our comprehensive live chart.

Hikma Pharmaceuticals plc. (HIK) creates and sells generic pharmaceutical solutions and products in the USA, North Africa, Europe, and the Middle East; with its headquarters located in London, UK. The company has operations in more than 50 countries and divides its work into three business units: Branded, Injectables, and Generics.

Hikma owns 29 manufacturing plants in 11 countries: Jordan, Saudi Arabia, Algeria, Egypt, Morocco, Tunisia, Sudan, United States, Portugal, Italy and Germany. The Hikma’s branded division offers 499 products in 1,256 dosage strength. The most popular products are: Amoclan, Omnisef, Blopress and Suprax. The injectables division vendors 200 products in 379 dosage forms.

Hikma pharmaceuticals share price is set and traded on the London Stock Exchange (LSE) under the ticker symbol HIK. The company constitutes the FTSE 100 and FTSE 350 Indices.

Hikma made an initial public offering on 11 November 2005, and Hikma pharmaceuticals shares were listed for the first time, raising gross proceeds of $124 million.

Hikma Pharmaceuticals was founded in Amman, Jordan, by Samih Darwazah in 1978. In August 1996, it became the first Arab company to export pharmaceutical products to the US.

The company’s biggest acquisitions include Jazeera Pharmaceutical, Saudi Arabia; Instituto Biochimico Pavese Pharma, Italy; Baxter International, US; Ribosepharm, Germany; Promopharm, Morocco, and Alkan Pharma, Egypt. All of these strategic acquisitions helped Hikma to establish itself as the world’s leading provider in its industry.

In May 2014, Hikma Pharmaceuticals plc significantly increased its presence in the injected medicine market by purchasing assets from the US generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million.

The most recent company acquisition was Roxane Laboratories in Columbus, US. It has majorly improved Hikma's position in a non-injectables business in the US market.

Hikma has been recognised as the Company of the Year by the Global Generics and Biosimilars Awards for four years in a row: from 2014 to 2017. 

According to Hikma’s latest earnings report, the company delivered strong growth in revenue and profit in 2019 with a group core revenue of $2,203 million (up 6 per cent) and operating profit of $508 million (up 10 per cent).

Follow the Hikma share price today with Capital.com to spot the best trading opportunities. Track all the ups and downs of the HIK stock price and stay on top of the latest price fluctuations with our live Hikma stock chart.

Latest shares articles

Top 5 biggest short squeezes
Top 5 biggest short squeezes
Top 5 biggest short squeezes
an hour ago
Market Mondays: Equities shrug off trade threats—but correction risk builds
Market momentum remains strong despite Trump's latest tariff threats as hope for deals continues
5 hours ago
UK GDP contracts again in May as FTSE 100 eyes new highs
The UK economy experiences negative growth in May leading markets to price in a rate cut from the BOE in August
08:31, 11 July 2025
Nvidia stock forecast: Third-party price target
Nvidia stock forecast: Third-party price target
Discover third-party Nvidia stock forecast predictions for 2025-2030 and beyond, with analyst targets, historical prices, and trading strategies.
14:51, 10 July 2025

Read our reviews to find out more about us

Read the feedback from our clients, whatever their experience level.
2025-07-01
Victor Flemming Nandwa Søder

Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.

2025-07-01
Perry Reineke

I'm learning the basics of stock investing. This platform is clear and pretty good. I've been using it for over 6 months.

2025-06-29
proinpro

Capital is really great to be used on start, also beginner friendly broker! Great costumer support and it is quick!

2025-06-27
Gio Gvazava

Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.

2025-06-22
Douglas

Deposits and withdrawals work without issues. Very low spreads. No noticeable fees. Easy to follow.

2025-06-22
Jean A.

The app is built to make options and figures easy to understand, great for beginners and intermediate traders. Demo accounts are simple to set up. 100:1 leverage is available.

2025-06-19
foobarbeer

I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.

2025-06-19
Casaubon70

Love the TV integration. Makes traders life smooth and comfortable.

2025-06-19
dgogidze7

I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️

2025-05-30
Brigman

Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.

2025-05-24
Radioilluminati

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-04-29
dmjnoor

This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one

2025-05-20
GemzT

I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!

2025-03-24
Debbie P

The best trading company I've found so far and so easy to use.

2025-02-06
Nouman Butt

User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.

Showing our 4 & 5 star reviews.

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading CFDs